Mid Pharma Sector: In-licensing and other externalization strategies
Introduction
Mid Pharma companies are EU/US based pharmaceutical companies with 2005 annual revenues of < $10bn. An integral component of the Mid Pharma business model is securing access to promising new drugs through in-licensing and acquisition.
Scope of this report
- Segmentation of the Mid Pharma market by key attributes including revenue size, therapy area and geographic focus
- Analysis of how dependent each Mid Pharma company is on externalization to support current portfolios
- Examination of which types of externalization strategy are most popular in the Mid Pharma peer set
- Case studies of how domestic players such as Menarini and Almirall are operating as conduits to the highly fragmented local markets of Europe
Research and analysis highlights
Segmentation of the PharmaVitae Mid Pharma peer set of 22 companies into 5 clusters the 'Big 6', CNS-focus, CV-focus, small domestic and 'multi-business unit' clusters. Insight into the deep CNS cardiovascular therapeutic axis that runs through Mid Pharma with CNS (Lundbeck, Forest and Shire) and CV-focused (Servier, King, Menarini and Schwarz) players at either end of the spectrum with the 'Big 6' players located in the middle range, addressing a broad range of therapy areas. Analysis of how the level of externalization dependency varies within Mid Pharma, from highly committed in-licensors such as Forest to internally-sufficient operations such as Servier.
Key reasons to read this report
- Understand why the majority of Mid Pharma companies are committed to populating their portfolios by in-licensing and acquisition
- Identify which companies are appropriate licensing targets on the basis of their 'fit' according to their scale, therapeutic and geographic focus
- Learn which types of externalization strategy are responsible for the largest influx of product revenues to Mid Pharma
